Netherlands And Melbourne

VENLO, Netherlands and MELBOURNE, Australia, April 3, 2011 - -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million), or A$3.55 per share -- Unanimous support from Cellestis board of directors(2); QIAGEN granted options to acquire up to 19.9% of Cellestis ordinary shares under certain circumstances, subject to regulatory approvals -- Acquisition provides QIAGEN with exclusive access to QuantiFERON(R) technology for high sensitivity, early disease detection not possible with other diagnostic approaches -- QuantiFERON(R) technology successfully commercialized with two marketed Cellestis tests for detection of latent tuberculosis (TB) and life-threatening CMV virus -- QIAGEN to expand QuantiFERON(R) portfolio, migrate technology to QIAsymphony and QIAensemble platforms and leverage synergies with current QIAGEN assay portfolio and pipeline -- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth rates in 2012 QIAGEN N.V.